Direct Answer
190 SEC filers are classified under the Standard Industrial Classification code that describes the cns pharmaceuticals industry, and their latest annual reports show $454.1 billion of combined revenue and a median operating margin of -339.4%. Investors should still evaluate its revenue model, industry-specific KPIs, valuation framework and the risks that can change the group's economics.
Industry Overview
Central nervous system pharmaceutical companies develop and sell drugs for depression, epilepsy, schizophrenia, migraine and Parkinson's disease. The market is large but trials are difficult, and generics erode sales after exclusivity ends. The first numbers to compare across companies here are prescription volume and net price, pipeline stage and share of key drug classes.
Key Industry Metrics
- Prescription volume and net price: Number of prescriptions filled and price received after discounts. Together they show demand and pricing, and generic erosion shows up as falling price and volume.
- Pipeline stage: Where candidates stand from early trials to approval. Brain disorder trials are hard, so later stages matter more and early stages carry high risk.
- Share of key drug classes: Portion of prescriptions in a class, such as antidepressants or antiepileptics, going to a company's drugs. It reveals competitive position in crowded categories.
- Patent expiry timeline: Dates when exclusivity ends and generics may enter. Following expiry, branded sales often fall quickly, so timing shows how long revenue is protected.
- Payer coverage: Whether insurers cover a drug and under what conditions, such as step therapy. Restrictions can limit uptake even for effective drugs.
Primary Macro Drivers
- Prevalence and diagnosis rates: As more people are diagnosed and treated for depression, epilepsy and migraine, the pool of prescriptions grows, which supports volume for established drug classes.
- Regulatory approvals: A regulator's decision on approval and label wording sets which patients can use a drug, which shapes prescription volume and launch timing.
- Payer formulary decisions: Insurers decide which brands are preferred and which require step therapy, so formulary placement moves prescription volume and net price.
- New mechanism launches: New mechanisms that work for patients who failed older drugs can capture share and support pricing, which shows up in share of key classes.
Major Risks
- Trial failures: Brain drug trials often miss endpoints, so a negative result can remove expected revenue; watch pipeline stage and expected readout dates.
- Generic erosion: When exclusivity ends, generics take most prescriptions quickly and net price falls; watch patent expiry timeline against sales of key brands.
- Safety and abuse regulation: Drugs with misuse potential face limits on prescribing and dispensing, which can reduce volume or add compliance cost; watch regulatory actions and label changes.
- Pricing pressure: Insurers push for rebates and use prior authorization, lowering net price per prescription; watch the gap between list and net price.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Defensive |
| Capital Intensity | Medium |
| Regulatory Intensity | High |
| Industry Maturity | Mature |
| Geographic Importance | U.S. / Global |
CNS Pharmaceuticals Filers in the SEC Record
190 companies with annual reports in the dataset are classified by the SEC in the Standard Industrial Classification code 2834. Their latest fiscal years end between 2022 and 2026, and together they reported $454.1 billion of revenue. Median revenue growth over the prior year was 11.1%. Median operating margin was -339.4% and median net margin -202.0%. Median total liabilities were 40% of total assets, and 40 of 190 reported a profit in their latest year.
| Company | Revenue | Growth | Operating margin | Net margin | Year |
|---|---|---|---|---|---|
| Johnson & Johnson | $94.2 billion | 6.0% | n/a | 28.5% | FY 2025 |
| Eli Lilly & Co | $65.2 billion | 44.7% | n/a | 31.7% | FY 2025 |
| Pfizer Inc | $62.6 billion | -1.6% | n/a | 12.4% | FY 2025 |
| Abbvie Inc. | $61.2 billion | 8.6% | 24.6% | 6.9% | FY 2025 |
| Bristol Myers Squibb Co | $48.2 billion | -0.2% | n/a | 14.6% | FY 2025 |
| Abbott Laboratories | $44.3 billion | 5.7% | 18.2% | 14.7% | FY 2025 |
| Viatris Inc | $14.3 billion | -3.0% | -18.6% | -24.6% | FY 2025 |
| Vertex Pharmaceuticals Inc / Ma | $12.0 billion | 8.9% | 34.8% | 32.9% | FY 2025 |
The 8 largest of 190 by revenue. Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. A company's SIC code reflects its main business as the SEC records it, so it can differ from how an index provider or analyst classifies the company, and a diversified group appears under only one code.
Where to Go Next
The CNS Pharmaceuticals guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Contract Development & Manufacturing Organizations
- Clinical Workflow Software
- Contract Research Organizations
- Clinical Trial Technology
- Dental Equipment
- Clinical-Stage Biotechnology
- Dental Service Organizations
- Cell Therapy
Put it to work
Frequently Asked Questions
What are the main KPIs for the CNS Pharmaceuticals industry?
Key performance indicators for the CNS Pharmaceuticals industry include: Prescription volume and net price, Pipeline stage, Share of key drug classes, Patent expiry timeline, Payer coverage. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the CNS Pharmaceuticals industry?
The CNS Pharmaceuticals industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions.
What are the biggest risks in the CNS Pharmaceuticals industry?
The primary risks for CNS Pharmaceuticals companies include: Trial failures, Generic erosion, Safety and abuse regulation, Pricing pressure. Investors should assess each company's exposure to these factors and its track record of navigating them.